Kodiak Gas Services Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Kodiak Gas Services Inc. Common Stock trades at $50.07 (market cap $5.26B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Kodiak Gas Services Inc. Common Stock pays a 3.77% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kodiak Gas Services Inc. Common Stock for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| KGS | PCVX | |
|---|---|---|
Market Cap | $5.26B | $10.51B |
Volume | 2,807,958 | 2,644,694 |
Sector | Energy | Health |
52-Week High | $76.27 | $73.82 |
52-Week Low | $32.95 | $40.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.94B | $9.14B |
Dividend Yield | 3.77% | — |
Signals from Pluang's Aura AI — not financial advice
KGS trades at $52.00, down 0.93% on the day, with technical indicators showing a bearish trend. The company reported Q2 2026 revenue growth but missed earnings expectations for three consecutive quarters. Recent developments include a significant power supply agreement for West Texas data centers, positioning KGS for future growth in distributed power generation.
Despite recent earnings misses, analyst consensus remains strongly bullish with a $80.38 price target representing 55% upside potential. Key risks include execution challenges in expanding power capacity and continued earnings volatility. The company's strategic pivot toward data center power services offers substantial growth opportunity if successfully executed.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Kodiak Gas Services, Inc. is a Texas-based provider of large-horsepower contract natural gas compression services, operating a fleet of roughly 4.5 million revenue-generating horsepower for oil and gas producers and midstream companies across major US production basins, including the Permian, Eagle Ford, and DJ Basin.
Read more on KGS →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →